4//SEC Filing
Fatal Sigal 4
Accession 0001178913-23-002227
CIK 0001534248other
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 4:03 PM ET
Size
12.9 KB
Accession
0001178913-23-002227
Insider Transaction Report
Form 4
Fatal Sigal
Chief Financial Officer
Transactions
- Award
Option to Purchase American Depositary Shares
2023-06-14+102,860→ 167,860 totalExercise: $1.70Exp: 2033-06-14→ American Depositary Shares (102,860 underlying) - Award
Option to Purchase American Depositary Shares
2022-11-08+29,400→ 65,000 totalExercise: $2.11Exp: 2032-11-08→ American Depositary Shares (29,400 underlying) - Award
Option to Purchase American Depositary Shares
2021-11-11+35,600→ 35,600 totalExercise: $9.83Exp: 2031-11-11→ American Depositary Shares (35,600 underlying)
Holdings
- 5,209
American Depositary Shares
Footnotes (5)
- [F1]Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
- [F2]No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this form 4 for informational purposes only.
- [F3]Options granted under the Company's 2017 Equity-Based Incentive Plan (the "Plan") on June 14, 2023; 25% of the options vest and become exercisable following 12 months from the grant thereof and an additional 6.25% vests at the end of each calendar quarter thereafter such that the options are fully vested and exercisable on June 14, 2027, subject to acceleration upon a change in control pursuant to the terms of the Option Agreement ("CIC") by and between the Reporting Person and the Issuer and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).
- [F4]These options vest and become exercisable pursuant to the following schedule: 25% of the options shall vest on November 8, 2023, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).
- [F5]These options vest and become exercisable pursuant to the following schedule: 25% of the options vested on November 11, 2022, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control pursuant ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).
Documents
Issuer
Chemomab Therapeutics Ltd.
CIK 0001534248
Entity typeother
Related Parties
1- filerCIK 0001850994
Filing Metadata
- Form type
- 4
- Filed
- Jun 15, 8:00 PM ET
- Accepted
- Jun 16, 4:03 PM ET
- Size
- 12.9 KB